Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PRNP | P04156 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041859 | 0.88 | LMNA (0.52) | DHODHKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL8737365 | 0.86 | KDM4E (0.49) | DHODHMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL13232471 | 0.84 | DHODH (0.46) | DHODHMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL8738290 | 0.80 | MEN1 (0.39) | DHODHMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2794288 | 0.78 | DHODH (0.55) | DHODHMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2793084 | 0.78 | DHODH (0.52) | DHODHMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2793085 | 0.77 | DHODH (0.54) | DHODHMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL15233650 | 0.77 | PDGFRB (0.37) | DHODHMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL15233645 | 0.75 | DHODH (0.42) | DHODHMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL13232476 | 0.74 | KDM4E (0.52) | MEN1KMT2AKDM4ESMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029394-B2 | 2-phenyl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-12 | — | — | US | disclosed |
| US-9023866-B2 | 2-selenophene-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-05 | — | — | US | disclosed |
| US-9023867-B2 | Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-05 | — | — | US | disclosed |
| US-20130253006-A1 | 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-26 | — | — | US | disclosed |
| US-20130252999-A1 | 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-26 | — | — | US | disclosed |
| US-20130244983-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-19 | — | — | US | disclosed |
| US-8440692-B2 | Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2013-05-14 | — | — | US | disclosed |
| EP-2468747-A1 | 2-Selenophene-4-quinolones as anticancer agents | China Medical University (TW) | 2012-06-27 | — | — | EP | disclosed |
| EP-2455369-A1 | Derivatives of 2-aryl-4-quinolones having an aminoalkyl group as anticancer agents | China Medical University (TW) | 2012-05-23 | — | — | EP | disclosed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | disclosed |
| WO-2008070176-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244983-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, SLC20A1 | DHODH 690/4885MEN1 3325/4885KMT2A 3070/4885 |
| US-20130253006-A1 | 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | DDX5, DHX30, PPIP5K2 | DHODH 893/4885MEN1 2925/4885KMT2A 2349/4885 |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, DDX20 | DHODH 777/4885MEN1 3774/4885KMT2A 2887/4885 |
| US-20130252999-A1 | 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS | PPIP5K2, DDX5, DHX30 | DHODH 803/4885MEN1 3533/4885KMT2A 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.